Open Nav

SFA Therapeutics, LLC

  • Ira Spector, SFA Therapeutics

Seed Capital

  • Date:Wednesday, October 17
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:SFA Therapeutics, LLC is a development-stage bio-pharmaceutical company focused on a new advancement in the treatment inflammatory diseases. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's Disease, Psoriasis, Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), and even cancer. Our microbiome-derived drugs are derived from natural substances identified at Temple University, and enable a new platform for developing treatments potentially aimed at over 85 potential inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is Psoriasis and Liver Disease (Hepatitis B, NASH and HCC). Patents have been filed in both of these diseases, based on animal data in Liver Disease and on a small human case-controlled trial ex-US in Psoriasis. Additional patents are filed in Uveitis, CRS (CAR-T) and neonatal allergies.
  • Company Website:https://sfatherapeutics.com/
  • Company HQ City:Philadelphia, PA
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • CEO/Top Company Official:Dr. Ira Spector, CEO
  • Year Founded:2016
  • Main Therapeutic Focus:Inflammation
  • Lead Product in Development :SFA-001
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :7
  • Additional Information/Comments:Our current focus is on raising $1.5M in seed capital to enable demonstration of Proof of Concept (POC) in Psoriasis, and on continuing to build our intellectual property estate. Because these drugs are derived from Generally Regarded As Safe (GRAS) substances they are not expected to require genotoxic testing, and should enable a much faster development path than traditional pharmaceuticals. Our business plan is to develop R&D and licensing partnerships with major pharmaceutical and biotech companies in each key disease indication, and to rapidly develop these into treatments for patients. Payout for these types of deals can return significant multiples on the original investments.
  • Previous and Current Investors:Founder, Temple University
  • Size of Last Investment Round:1.5M
  • Total Amount Raised to Date, In All Rounds:100,000
Speakers
Ira Spector
SFA Therapeutics
Back